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Aims Increasing energy storage capacity by elevating creatine and phosphocreatine (PCr) levels to increase ATP
availability is an attractive concept for protecting against ischaemia and heart failure. However, testing this
hypothesis has not been possible since oral creatine supplementation is ineffectual at elevating myocardial creat-
ine levels. We therefore used mice overexpressing creatine transporter in the heart (CrT-OE) to test for the first
time whether elevated creatine is beneficial in clinically relevant disease models of heart failure and ischaemia/
reperfusion (I/R) injury.
Methods
and results
CrT-OE mice were selected for left ventricular (LV) creatine 20–100% above wild-type values and subjected
to acute and chronic coronary artery ligation. Increasing myocardial creatine up to 100% was not detrimental
even in ageing CrT-OE. In chronic heart failure, creatine elevation was neither beneficial nor detrimental, with
no effect on survival, LV remodelling or dysfunction. However, CrT-OE hearts were protected against I/R
injury in vivo in a dose-dependent manner (average 27% less myocardial necrosis) and exhibited greatly
improved functional recovery following ex vivo I/R (59% of baseline vs. 29%). Mechanisms contributing to is-
chaemic protection in CrT-OE hearts include elevated PCr and glycogen levels and improved energy
reserve. Furthermore, creatine loading in HL-1 cells did not alter antioxidant defences, but delayed mitochon-
drial permeability transition pore opening in response to oxidative stress, suggesting an additional mechanism
to prevent reperfusion injury.
Conclusion Elevation of myocardial creatine by 20–100% reduced myocardial stunning and I/R injury via pleiotropic mechanisms,
suggesting CrT activation as a novel, potentially translatable target for cardiac protection from ischaemia.
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1. Introduction
Directly increasing energy stores in the heart is an attractive strategy
for the treatment of ischaemic heart disease, but this is not currently
targeted by any available medication. One approach is to increase intra-
cellular creatine levels. Creatine kinase (CK) catalyses the reversible
transfer of a high-energy phosphoryl group from ATP onto creatine
to form phosphocreatine (PCr), which acts as an energy storage mol-
ecule, rapidly regenerating ATP at times of increased energy demand.1
Since impairment of this system is detrimental to functional recovery
following myocardial ischaemia,2,3 we hypothesized that augmenting
it, by increasing intracellular creatine, would be beneficial.
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There is a wealth of evidence that many components of the CK
system are impaired in chronic heart failure (CHF), regardless of aeti-
ology or species,4–6 and there exists a close relationship between a
low PCr/ATP ratio and mortality in human heart failure.7 A strategy
of reversing this energetic deficit is strongly supported by recent find-
ings that M-CK overexpression protects against heart failure in a
mouse pressure-overload model.8 We, therefore, also sought to
test whether elevated creatine would be beneficial in CHF.
Increasing creatine levels in the heart to test these two hypotheses
is not straightforward. Cardiomyocytes cannot synthesize creatine,
which enters the cell via a specific creatine transporter (CrT).
Simply increasing dietary creatine does not result in elevated tissue
creatine in the mature heart due to subsequent down-regulation of
the CrT.9 To circumvent this feedback-loop, we previously created
mice that constitutively overexpress the CrT in the heart (CrT-OE
mice). These mice accumulated creatine to very high levels (four-fold
above wild-type), which was associated with left ventricular (LV)
hypertrophy and dysfunction.10,11
To determine whether the theoretical benefits of elevating creatine
can be realized (free of adverse effects), we have used CrT-OE mice
with more modest increases in myocardial creatine (20–100%
above normal values). We establish that this range is not deleterious
to the heart, even within the setting of CHF, and find that elevated
creatine is cardio-protective in models of ischaemia/reperfusion via
pleiotropic mechanisms. This work establishes elevating creatine by
augmenting CrT function as a potentially translatable target to
protect against myocardial ischaemia.
2. Methods
2.1 Mouse strain used
Transgenic mice overexpressing the creatine transporter (CrT-OE) using
a cardiomyocyte-specific promoter (MLC2v) have previously been
described in our laboratory.10 Two strains were created exhibiting a
wide range of myocardial creatine from normal to .four-fold above wild-
type values. Creatine variability was related to differences in transgene
mRNA expression rather transgene copy number or number of integra-
tion sites. These mice were back-crossed to C57BL/6J for .10 genera-
tions with wild-type littermates used as controls. For the current study,
mice were selected for moderate elevation of creatine of between 20
and 100% above WT either in vivo by 1H-MRS or on post-mortem
tissue by HPLC. Mice from the Tg46 strain were used preferentially as
the frequency distribution is closer to this target range. Mice were kept
in specific pathogen-free cages, 12-h light–dark cycle, controlled tempera-
ture and humidity, and fed standard chow (naturally creatine-free) and
water ad libitum. This investigation was approved by the institutional
ethical review committee and conforms to Directive 2010/63/EU of the
European Parliament.
2.2 Left ventricular haemodynamics
In vivo LV haemodynamics were performed in closed-chest freely breath-
ing mice under isoflurane general anaesthesia (1–1.5% in medical oxygen)
as previously described.10 An adequate anaesthetic depth was determined
by the absence of the pedal reflex. The jugular vein was cannulated for the
administration of dobutamine at 16 ng/g body weight/min for maximal ino-
tropic stimulation. Measurements were made in n ¼ 31 WT and n ¼ 31
CrT-OE mice (17 males and 14 females in each) at 18 months of age
(79+ 1 weeks). There was no difference between sexes, therefore
males and females were analysed together. Mice were euthanized by
cervical dislocation and LV tissue snap frozen in liquid nitrogen for the de-
termination of creatine levels by HPLC.
2.3 Chronic myocardial infarction protocol
A total of 67 female mice aged 4–8 months had 1H-MRS examination
so that CrT-OE mice could be selected for total creatine in the range
88–140 nmol/mg protein. Mice meeting these criteria received a
cine-MRI examination 1 week prior to surgery to ligate the left anterior
descending coronary artery. An echocardiogram was performed at 4
weeks to exclude mice with infarct sizes ,25%. Cine-MRI was repeated
6 weeks after surgery followed by LV haemodynamics (as described
above). Six mice were excluded in order to retrospectively match
infarct sizes between groups.
2.4 1H-MRS and cine-MRI
All MR experiments were carried out on a 9.4T (400 MHz) MR system
(Agilent Technologies) using a quadrature-driven birdcage resonator
(Rapid biomedical). Mice were anaesthetized with isoflurane and main-
tained at 1.5–2% in oxygen. Monitoring of ECG and the respiration
rate ensured the stable depth of anaesthesia. Cardiac metabolite signals
from a 2 mL voxel, placed in the interventricular septum, were acquired
using a double-gated, double spin-echo sequence as reported previous-
ly.12 Analysis and quantification of these spectra are described in the Sup-
plementary material online, Methods. Global cardiac functional
parameters were measured from multi-frame short-axis gradient-echo
images covering the heart from the base to the apex. The infarct size
(in % of total LV) was measured using ImageJ (version 1.44).
2.5 Coronary artery ligation surgery
Permanent ligation of the left anterior descending (LAD) coronary artery
as previously described.5 Briefly, general anaesthesia was induced in
female adult mice with 4% isoflurane in medical oxygen followed by oro-
pharyngeal intubation for mechanical ventilation with 2% isoflurane at
250 mL stroke volume and 150 b.p.m. An adequate anaesthetic depth
was confirmed by the absence of the pedal reflex. Buprenorphine anal-
gesia was provided (1 mg/kg subcutaneous) prior to surgery. A thoracot-
omy was performed between the 4th and 5th ribs, the pericardium
removed, and the LAD occluded using a 6–0 polyethylene suture
(infarct confirmed by blanching of the myocardium). The chest wall was
closed and 1 mL subcutaneous saline administered prior to recovery.
Mice were provided with softened chow and supplementary heat until
fully recovered.
2.6 Ischaemia/reperfusion injury in vivo
For permanent occlusion, surgery was as above, but with the reperfusion
of the coronary artery after 45 min of ischaemia, confirmed by direct visu-
alization of blood returning to infarcted myocardium. A total of n ¼ 53
CrT-OE and WT mice aged 4–5 months and n ¼ 6 C57BL/6J mice as a
positive control group treated with ischaemic postconditioning (IPC) con-
sisting of three cycles of 10 s reperfusion and 10 s ischaemia immediately
after the main period of ischaemia. A further n ¼ 14 C57Bl/6J mice served
as non-IPC controls and were combined with the WT control group for
analysis purposes. At 24 h, mice were killed by the excision of the heart
under deep isoflurane anaesthesia. Area-of-necrosis and area-at-risk
were then assessed histologically using tetrazolium staining as previously
described.13 The right ventricle was snap frozen in liquid nitrogen for
retrospective quantification of creatine by HPLC.
2.7 Ischaemia/reperfusion recovery ex vivo
A total of n ¼ 9 CrT-OE mice and WT littermates (four females and five
males of each) were heparinized (5000 U/kg body weight) and anaesthe-
tized (pentobarbitone 140 mg/kg ip). Hearts were excised, cannulated and
perfused in the Langendorff mode inside a 10-mm NMR tube at 80 mmHg
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and 378C with Krebs–Henseleit buffer gassed with 95% O2/5% CO2. The
LV function was assessed using a fluid-filled intraventricular balloon
connected to a pressure transducer (ADInstruments Ltd). The end-
diastolic pressure was set to 10 mmHg.31P-NMR spectra of perfused
mouse hearts were acquired on a Bruker Avance 500 spectrometer
equipped with an 11.7T magnet and a 20 mm 1H-/31 P-crosscage
resonator.31P spectra were acquired using a pulse-and-collect sequence
with a repetition time (TR) of 2 s and a flip angle of 608 with 150 averages
each (5 min per spectrum) and were corrected for partial saturation. Pre-
ischaemic ATP levels were normalized to previously published baseline
values,10 with absolute PCr and inorganic phosphate (Pi) calculated
from the measured PCr/ATP and Pi/ATP ratios. Intracellular volume was
assumed to be 0.5 mL/g wet weight. Intracellular pH was determined
from the chemical shift d between the Pi and PCr peaks using the equation
pH ¼ 6.72 2 log(d2 5.72)/(3.172 d). The free-energy change of ATP
hydrolysis (△G; in kJ/mol) was calculated from the CK equilibrium as-
sumption as previously described.4 After a 10 min period of control per-
fusion, hearts were subjected to 20 min of global normothermic no-flow
ischaemia, followed by a 30 min reperfusion period. Rate pressure
product (RPP) was calculated as the product of heart rate and LV devel-
oped pressure (systolic – diastolic pressure).
2.8 Biochemical analysis
Frozen crushed ventricular tissue or cells were prepared for the measure-
ment of CK activity and/or the quantification of creatine by HPLC, and
then normalized to protein content using the Lowry method as previously
described.14 The myocardial glycogen content was determined spectro-
photometrically as glucose equivalents after digestion of tissue with 30%
KOH, ethanol precipitation, and acid hydrolysis of glycogen as described
in the Supplementary material online, Methods. Immunoblotting for phos-
phorylated PKC delta and cleaved Caspase-3 used total protein extracted
from LV tissue following ex vivo ischaemia/reperfusion as described above.
Expression levels were detected with the ECL Advance chemilumines-
cence kit (GE Healthcare, Amersham, UK) and a FluorChem 8800
imager. For quantification, blots were stripped and re-probed for
b-tubulin as described in Supplementary material online, Methods.
2.9 Oxidative stress protection assay
Oxidation of 2′,7′dichlorodihydroflourescein diacetate (H2DCF-DA) by
H2O2 in vitro was adapted from Young et al.
15 A cell line stably expressing
the rabbit creatine transporter (3T3-CrT-HA) and atrial tumour-derived
mouse HL-1 cells were used for this purpose. Cells were plated onto
96-well plates at a density of 0.2 × 105 cells/well and creatine monohy-
drate added to culture media at 250, 500 mM, 5 and 10 mM for 24 h. Cul-
tures were then washed with phosphate-buffered saline and loaded with
10 mM H2DCF-DA (Molecular Probes, Life Technologies, Paisley, UK) in
Hanks’ balanced salt solution for 30 min at 378C (95% air, 5% CO2).
Cells were then exposed to 100 mM H2O2 with or without Trolox
(12 nmol; BDH Prolabo VWR, UK) as a positive antioxidant control. Oxi-
dation of intracellular H2DCF-DA was determined by increase in fluores-
cence at excitation and emission wavelengths of 485 and 520 nm at 378C
with a microtitre plate reader (POLARstar Omega, BMG Labtech, Ayles-
bury, UK). Data were recorded every 5 min and were collected in three
independent experiments, having n ¼ 6 replicates per treatment group.
2.10 mPTP opening assay
The effect of intracellular creatine on opening of the mitochondrial perme-
ability transition pore (mPTP) was assessed in vitro in HL-1 cells loaded with
tetramethylrhodamine methyl ester (TMRM), as previously described.16
HL-1 cells were seeded onto gelatin/fibronectin-coated 35-mm confocal
dishes at a density of 1–2 × 105 cells/dish, and incubated for 24 h in
either standard Claycomb medium (Sigma, F2442), or Claycomb medium
supplemented with 5 or 10 mM creatine. Cells were loaded with 3 mM
TMRM (Sigma, T5428) in Hank’s buffered salt solution (HBSS with Ca2+,
Sigma, H8264) for 15 min at 378C. As a positive control, some samples
were supplemented with 0.5 mM cyclosporin A (CsA) (Merck, 239835).
Photoactivation of TMRM was induced using the 1.2 mW 543 nm
He–Ne laser of a Zeiss LSM510 confocal microscope. Laser power (5%),
detector gain, and optical settings were identical for all experiments. The
time to a 50%-maximal increase in TMRM fluorescence was taken as a
measure of mPTP opening. For statistical analysis, the results from four in-
dependent experiments were normalized to their respective control values
and the data averaged for between groups comparison.
2.11 Data analysis
All measurements were analysed blind to the genotype and creatine
levels. Data are expressed as mean+ SEM. Unless otherwise stated, stat-
istical comparison between two groups at a single time-point was by Stu-
dent’s t-test, and between three groups by one-way ANOVA. Comparison
between groups at multiple time-points was analysed by two-way
repeated measures (mixed model) ANOVA with a Bonferroni correction
for multiple comparisons. A log-rank (Mantel-Cox) test was used to de-
termine whether survival curves were statistically different. Differences
were considered significant when P, 0.05.
3. Results
3.1 Long-term moderate elevation
of myocardial creatine is safe
To determine a safe level of creatine elevation, in vivo LV haemo-
dynamic measurements were performed in CrT-OE and WT litter-
mate controls at 18 months (n ¼ 31 of each). Mean myocardial [Cr]
was 74+6 in WT and 119+ 16 nmol/mg protein in CrT-OE mice
(maximum 138). No significant differences were observed for any
functional parameters (Supplementary material online, Figure S1A–F).
Mean values for LV/body weight were 2.79+ 0.43 WT vs. 2.97+
0.43 mg/g CrT-OE (P ¼ ns), and there was no correlation with LV
creatine levels (Supplementary material online, Figure S1G). In con-
trast, n ¼ 10 mice excluded due to high creatine (mean 152+
10 nmol/mg protein; range 141–167) had significant LV hypertrophy
with LV/body weight 3.21+ 0.35 mg/g (P ¼ 0.007 vs. WT). There-
fore, mice with total myocardial creatine .140 nmol/mg protein
were excluded from all subsequent experiments.
3.2 Effect of creatine on LV remodelling
and function in chronic heart failure
CrT-OE mice were pre-selected for myocardial creatine in the range
88–140 nmol/mg protein by 1H-MRS and subjected to permanent
ligation of a coronary artery to induce myocardial infarction (MI).
There was no significant difference in all-cause mortality over 6
weeks between WT and CrT-OE mice (31 vs. 33%; P ¼ 0.78). For
all further analysis, WT and CrT-OE mice were retrospectively
matched for the infarct size in order to study the effect of creatine
on heart failure independently of any effect on myocardial injury: WT
mean 36%, range 29–50; CrT-OE mean 37%, range 30–50 (n ¼ 10
in each). Total LV creatine levels were higher at baseline in CrT-OE
mice compared with WT and remained significantly higher despite a
fall in creatine in both groups characteristic of CHF (Figure 1A).
There were no significant differences in baseline structural or func-
tional parameters by cine-MRI between WT and CrT-OE mice (open
circles in Figure 1B–E). Six-week post-MI, all animals had highly signifi-
cant LV hypertrophy, dilatation, and dysfunction compared with the
baseline, consistent with the development of CHF, but there were
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no significant differences between WT and CrT-OE mice, and no re-
lationship between LV creatine and ejection fraction (triangles
Figure 1B–F). In vivo LV haemodynamics confirmed these findings
(Supplementary material online, Table S1).
3.3 Elevated creatine reduces myocardial
injury following ischaemia/reperfusion
in vivo
Male mice had 45 min of regional ischaemia followed by 24 h reperfu-
sion. The mean myocardial [Cr] was 75% higher in CrT-OE mice
(Supplementary material online, Table S2). Area-at-risk was compar-
able between groups at 45–46% (Figure 2A), whereas mice with ele-
vated creatine had 27% less myocardial necrosis, P, 0.05 (Figure 2B).
There was an inverse correlation between the infarct size and LV cre-
atine levels, with higher creatine being associated with smaller infarct
sizes (Figure 2C with examples in Figure 2D). Mice with IPC were
included to compare the size of effect: infarct sizes were 31, 23, and
18% for WT, elevated creatine, and IPC groups, respectively.
3.4 Elevated creatine improves functional
recovery following I/R ex vivo
Langendorff-perfused WT and CrT-OE hearts were subject to 20 min
global ischaemia and 30 min reperfusion. At baseline there were no
significant differences in any functional parameters (Supplementary
material online, Table S3). Upon reperfusion CrT-OE hearts had sig-
nificantly higher LV systolic pressure and RPP during the last 20 min
of ischaemia (Supplementary material online, Table S3 and
Figure 3A). Diastolic pressure during reperfusion increased to the
same extent in both groups (Figure 3B). During the onset of ischaemia
functional data were analysed at high temporal resolution (1 s). It took
twice as long for RPP to decline to 25% of baseline in CrT-OE hearts
(Figure 3C). A similar effect was observed on return to function at
reperfusion, with 50% of baseline RPP achieved 12 s quicker in the
CrT-OE hearts (P, 0.05; Figure 3D). Both groups had a period of
hyper-contractility on initial reperfusion, but in CrT-OE hearts this
phase was transient, whereas in WT this phase was markedly
prolonged.
Figure 1 Elevated creatine is neither beneficial nor detrimental in chronic heart failure. Experimental groups were matched for the infarct size
(n ¼ 10 in each). (A) Myocardial creatine measured pre-MI (open circle) by 1H-MRS and post-MI (filled triangle) by HPLC. CrT-OE mice had elevated
creatine throughout the experiment (*P, 2 × 10–7 vs. WT at same time-point; #P, 0.05 pre-MI vs. post-MI). (B–E) MRI parameters measured
before and after MI. There was no effect of the genotype by 2-way ANOVA, while MI resulted in major changes in all parameters in both groups
(P, 0.0001). (F) There was no correlation between ejection fraction and final myocardial creatine levels.
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3.5 Cardiac energetics during ischaemia/
reperfusion
Using 31P-MRS, baseline myocardial PCr levels were 49% higher in
CrT-OE hearts compared with WT littermates (21.1+ 1.6 vs.
14.2+ 0.6 mM, respectively, P, 0.01; Figure 4A), with no significant
difference in Pi or pH (Figure 4C and D). During ischaemia, the relative
breakdown of PCr and ATP and the consequent increase in Pi was in-
distinguishable between groups within the available temporal reso-
lution of 5 min (Figure 4A–C). Intracellular pH fell to 6.08 and 6.12
in control and CrT-OE hearts, respectively, and quickly recovered
during reperfusion. PCr rapidly recovered to near baseline in both
groups, but returned to higher values in CrT-OE hearts. ATP concen-
trations recovered only partially and to the same extent in both groups.
Pi levels rapidly declined, in line with the rapid re-phosphorylation of
Cr, but remained higher in the control hearts than in the CrT-OE
hearts (Figure 4C; P ¼ 0.02). There was a trend for lower ADP levels
in CrT-OE hearts, e.g. during the reperfusion phase WT 133+35 vs.
CrT-OE 77+16 mM (P ¼ 0.16). However, Gibbs free energy change
of ATP hydrolysis was greater in CrT-OE hearts, both at baseline and
during reperfusion (Figure 4E; P ¼ 0.04), suggesting that more energy
was available per molecule of ATP. Under normal baseline conditions
the myocardial glycogen content was significantly higher in CrT-OE
compared with WT (P ¼ 0.003), and there was a positive correlation
with total creatine levels (Figure 4F).
To determine whether improved functional recovery was related
to reduced cell injury in this acute model, we measured protein ex-
pression of cleaved caspase-3 and phosphorylated-PKCd as early
markers of commitment to apoptosis, and no differences were
observed between groups (Supplementary material online, Figure S2).
3.6 Creatine does not provide protection
via direct antioxidant activity
To determine whether creatine has antioxidant effects that could con-
tribute to the cardio-protective mechanisms, we used a direct
measure of antioxidant activity in a cell-based assay system. Cells
loaded with the dye H2DCF-DA which fluoresces only in the oxidized
form, produced a robust increase in fluorescence upon challenge with
H2O2. Pre-incubation with a known antioxidant (Trolox) attenuated
this response (Figure 5). Fibroblasts constitutively overexpressing the
CrT were incubated for 24 h with creatine, resulting in elevated intra-
cellular creatine levels (Table 1). Creatine did not attenuate the re-
sponse to H2O2 (Figure 5A and B). Identical results were obtained
when the experiment was repeated in the cardiomyocyte-derived
HL-1 cell line (Figure 5C and D). Creatine levels in HL-1 cells after
Figure 2 Elevated myocardial creatine protects against in vivo I/R injury (45 min ischaemia, 24 h reperfusion). (A) There was no difference in
area-at-risk (AAR) between groups. (B) Mice with elevated LV total creatine ([Cr] ¼ 94–137 nmol/mg protein; n ¼ 22) had significantly less myocar-
dial necrosis compared with control mice (n ¼ 25), to a level indistinguishable from ischaemic postconditioning (IPC, n ¼ 6; mean+ SEM). (C) There
was a significant inverse correlation between infarct size and LV creatine. Open squares represent WT mice and black circles CrT-OE mice. (D) Rep-
resentative LV histological sections arranged from the base to the apex. Unaffected myocardium is stained blue, necrotic areas are white, and
area-at-risk is red + white.
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24 h exposure show an increase similar in magnitude to the in vivo
CrT-OE mouse heart (Table 1).
3.7 Creatine attenuates mitochondrial
permeability transition pore opening
Opening of the mPTP is a seminal event determining the extent of
reperfusion injury, therefore the ability of intracellular creatine
levels to modulate mPTP opening was assayed in HL-1 cells loaded
with the mitochondrial permeable dye, TMRM. Illumination with
laser light generates reactive oxygen species that provide stimulus
for pore opening, observed as a gain in fluorescence signal as dye
released into the cytosol becomes dequenched. Using CsA as a posi-
tive control, we observed a prolongation in time to 50% of maximal
response, representing protection from mPTP opening (Figure 6). In-
cubation of cells for 24 h with creatine resulted in elevated creatine
and PCr levels and induced expression of the B-CK isoform
(Table 1). Both 5 mM and 10 nM creatine concentrations were as ef-
fective as CsA at delaying mPTP opening. This is illustrated in the
example experimental trace shown in Figure 6A. The same pattern
of protection was observed in all four independent experiments
(Figure 6B), which were then normalized to control values and aver-
aged as shown in Figure 6C.
4. Discussion
Our study establishes the elevation of creatine by augmenting CrT
function as a therapeutic principle in ischaemia/reperfusion injury.
This circumvents the difficulty of increasing intracellular creatine in
the adult cardiomyocyte and has allowed us to test the concept of
elevating myocardial creatine as a therapeutic strategy for the first
time.
Our first step was to establish a safe range for creatine elevation in
the heart. Using data from our earlier studies,10,11 a cut-off of
140 nmol/mg protein was selected. We clearly demonstrate that pro-
longed elevation of myocardial creatine up to this level, which is
100% above normal values, is safe and does not result in LV hyper-
trophy even in mice up to 18 months of age. This provided a thera-
peutic window to investigate our hypotheses.
We did not observe a beneficial effect of elevated creatine in CHF.
One limitation is that mice have relatively low starting creatine com-
pared with larger species and the fall in levels during heart failure is
less pronounced.5 This might negatively impact on our ability to
detect a protective effect in the mouse, especially since the mechan-
isms underpinning such species difference are unclear. Nevertheless, it
is an important finding that creatine is safe within this setting. More
refined approaches involving creatine may yet hold promise in CHF.
For example, in silico modelling has predicted benefits from the eleva-
tion of creatine in combination with total adenine nucleotides and
total exchangeable phosphate pools.17 More recently, overexpression
of M-CK in the mouse heart was shown to protect against LV dysfunc-
tion in a model of heart failure,8 and there is a clear rationale in
simultaneously increasing both CK activity and creatine, i.e. substrate
and enzyme together.
The in vivo cardio-protective effect of creatine was comparable in
scale to IPC, an intervention that has been shown to strongly
Figure 3 Function in isolated-perfused hearts during 20 min global no-flow ischaemia (grey) and 30 min reperfusion. (A) CrT-OE hearts had better
functional recovery during reperfusion. RPP is rate pressure product (developed pressure × heart rate) expressed as % of baseline with data points at
2.5 min intervals (B) Left ventricular end-diastolic pressure (LVEDP) rises during reperfusion to the same extent in both groups. (C ) Initial onset of
ischaemia at 1 s temporal resolution showing contractile function is maintained for longer in CrT-OE hearts. (D) Detailed analysis of data shown in (A)
focusing on early reperfusion with 1 s temporal resolution showing a different pattern of hypercontractility upon reperfusion, i.e. onset is slower but
response is prolonged in the WT hearts. *P, 0.05.
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attenuate I/R injury in mice.18 However, we cannot rule out that
chronic overexpression of CrT could have resulted in adaptations
that contributed to this effect and unfortunately our attempts to
create an inducible model of CrT-OE to address this question were
unsuccessful. Improved functional recovery was demonstrated ex
vivo, with simultaneous 31P-MRS data suggesting several potential pro-
tective mechanisms.
4.1 PCr as energy store
Myocardial PCr levels were 49% higher in CrT-OE mice, which could
act like a back-up battery, effectively reducing ischaemic time. Normal
metabolic demand for the contracting heart is 1 mM of ATP per
second,4 so this effect will not be prolonged and was not reflected
in PCr or ATP depletion rates, likely due to insufficient temporal reso-
lution (5 min). However, CrT-OE hearts maintained contractile func-
tion for longer, which returned more rapidly upon reperfusion.
Although small, this effect may be physiologically relevant, since
small changes in ischaemic time are known to have a disproportionate
effect on the myocardial injury size.19,20 Furthermore, a larger effect
of PCr on basal metabolism during ischaemia cannot be discounted.21
4.2 PCr maintains favourable ATP/ADP
ratio and therefore DG of ATP hydrolysis
The PCr/CK system also functions to keep local free ADP concentra-
tions low, which is important for maintaining high DGATP, i.e. the energy
liberated from ATP hydrolysis and available to perform work.22 The
value for DGATP in the normal rodent heart is 255 to 260 kJ/mol,
4
and many key ATPases cease to function properly when DGATP falls
below a certain threshold value, e.g. Na+–K+–ATPase at
250 kJ/mol23 and sarco(endo)plasmic reticulum Ca2+-ATPase
(SERCA) at 252 kJ/mol. The difference between |DGATP| and the
threshold value is termed ‘energy reserve’,4 and represents the chem-
ical potential driving ATPase activity. It is notable that DGATP started
higher in the CrT-OE mice and returned to normal values within
minutes of reperfusion. In contrast, WT hearts did not return above
253 kJ/mol, very close to the threshold for SERCA pump function.
Both experimental groups had a hyper-contractile phase peaking
60 s into reperfusion, the inotropic consequence of intracellular
calcium accumulation during ischaemia.24,25 That this returns to
normal more rapidly in CrT-OE represents indirect evidence for
improved ion homoeostasis and suggests the effect of low energy
Figure 4 Ex vivo 31P-MRS during 20 min global ischaemia and 30 min reperfusion in CrT-OE and wild-type hearts. (A) Phosphocreatine, PCr; (B)
ATP; (C) inorganic phosphate, Pi; (D) intracellular pH, pHi; (E) free energy change of ATP hydrolysis, DGATP; (F) the myocardial glycogen content
at baseline is 2.8-fold higher in CrT-OE mice (t-test, P ¼ 0.003) and positively correlates with creatine levels. Data are mean+ SEM and P-value is
for the effect of the genotype by two-way repeated measures ANOVA.
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reserve is more than just theoretical. This suggests that WT experi-
enced a relatively longer period of calcium overload, which is
known to be detrimental, for example, the impairment of SERCA
function increases calcium accumulation and results in greater I/R
injury,26 as does knockout of CK.2
4.3 Effect on glycogen storage
During ischaemia, generation of ATP is dependent on glycogen as the
only substrate available for glycolysis.27 We observed 2.8-fold higher
levels of glycogen in hearts from CrT-OE mice compared with WT,
which in rabbit hearts have been shown to reduce ischaemic
damage and improve recovery.28
4.4 Oxidative stress and mPTP opening
Other studies have shown direct antioxidant effects of (phospho-)
creatine,29,30 however, we were unable to detect protection from
H2O2 challenge in cells with intracellular levels of creatine that corres-
pond with our in vivo ‘therapeutic range’. In contrast, we clearly dem-
onstrate that elevated creatine was as effective as CsA in prolonging
time to mPTP opening in an assay that models the burst of reactive
Figure 5 Creatine does not have direct anti-oxidant activity. Cells were loaded with the dye H2DCF-DA and exposed to 100 mM H2O2 resulting in
oxidation of dye, measured as an increase in fluorescence. Pre-incubation with varying concentrations of creatine (Cr) for 24 h increased intracellular
creatine levels, but did not alter the fluorescent signal. In contrast, the anti-oxidant trolox (12 nmol) significantly attenuated oxidation of dye by H2O2
(**P, 0.01). An identical pattern was observed in two cell types: 3T3 fibroblasts overexpressing the creatine transporter (CrT), and in
cardiomyocyte-derived HL-1 cells. Example traces from a single experiment are shown in (A) and (C), with mean data in (B) and (D).
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 1 Creatine levels and creatine kinase activity in cells cultured with and without creatine
3T3-CrT cells HL-1 cells
Control 15 mM Cr Control 15 mM Cr
Creatine (nmol/mg protein) 33.8+0.5 54.7+0.5 20.0+0.4 52.0+0.8
Phosphocreatine (nmol/mg Pr) 2.4+0.1 1.8+0.1 5.2+0.2 16.5+0.4
Total CK activity (IU CK/mg Pr) ND ND 0.32+0.01 0.31+0.01
Mito-CK ND ND 0.21+0.01 0.19+0.00
MM-CK ND ND 0.12+0.02 0.07+0.01
MB-CK ND ND ND 0.02+0.00
BB-CK ND ND ND 0.04+0.00
Data are mean+ SD. CK, creatine kinase; ND denotes below limits of detection. Cells incubated in normal culture media (control) or supplemented with 5 mM creatine monohydrate for
24 h.
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oxygen species associated with reperfusion. This assay does not
induce ischaemia, therefore the energetic mechanisms described
above are unlikely to contribute, and we have excluded a direct anti-
oxidant effect of creatine. The precise mechanism of action remains to
be elucidated, however, overexpression of mitochondrial-CK in the
liver can reduce mPTP opening, with the presence of creatine obligate
for this effect.31 This is a potential mechanism here, since we demon-
strate that HL-1 cells express enzymatically active CK (including
mitochondrial-CK), although we cannot rule out a direct effect of cre-
atine itself to influence pore opening.
4.5 Limitations and potential clinical
relevance
We cannot rule out that chronic overexpression of CrT may have
resulted in adaptations that contribute to our cardioprotective
effect. Our previous attempts to create an inducible model of
CrT-OE were unsuccessful and there are no pharmacological modu-
lators currently available to test this. Translation of our own findings
will therefore require the development of the necessary pharmaco-
logical tools targeting the CrT. While genetic overexpression led to
variation in the creatine content due to variability in transgene
mRNA expression,32 a drug-based approach mimicking post-
translational regulation should provide more reproducible creatine
levels. Furthermore, the kinetics of creatine accumulation and elimin-
ation are favourable, and can be monitored non-invasively using
1H-MRS. For example, the CrT is highly inducible, capable of increas-
ing activity up to seven-fold above baseline.32 Loss of tissue creatine is
a slow process via non-enzymatic cyclization to creatinine (1.6% of
creatine pool per day),33 suggesting that a single boost in creatine
levels will have prolonged effects. Clinical applications of a putative
CrT activator might include patients with unstable angina at risk of
an imminent MI; patients undergoing cardiac surgery with cardioplegic
arrest; and patients with stable angina, where a shift in the ischaemia
threshold on exercise would improve symptoms.
Summary and conclusions
We have demonstrated that elevation of creatine by up to 100%
above normal values by increasing CrT activity is not detrimental to
the heart even over prolonged periods, and importantly, is well toler-
ated even in the presence of CHF. Although creatine does not
improve function in the failing heart, it does protect against ischaemia/
reperfusion injury and associated myocardial stunning. The mechan-
isms in the acute setting are attributed to a combined effect on
cardiac energetics by increasing PCr buffer capacity, increasing myo-
cardial glycogen, and improving ‘energy reserve’. Protection from
ischaemia/reperfusion injury is likely to be a combination of down-
stream benefits of improved functional recovery and an effect of
creatine to reduce probability of mPTP opening. CrT activation may
become a clinically translatable target for anti-ischaemic therapy.
Supplementary material
Supplementary material is available at Cardiovascular Research online.
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levels, including a method for screening compounds that modulate the
creatine transporter.
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